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Purpose. The aim of this study was to retrospectively evaluate if the occurrence of 
neutropenia is correlated with response to second-line treatment with ramucirumab 
plus paclitaxel for metastatic gastric cancer.  
Methods. This is a retrospective study of patients treated with ramucirumab plus 
paclitaxel. 
Results. Fifty-three patients were retrospectively evaluated. Among these, 10 
patients (26,5%) developed grade ≥3 neutropenia during treatment but showed better 
outcome compared to those reported lower grade events. Patients with grade ≥3 
neutropenia reported a progression-free survival (PFS) of 6.6 months (95% CI 3.3-
8.4) and overall survival (OS) of 11 months (95% CI 5.9-13.1) versus 4.4 months 
(95% CI 3.9-5.2) PFS and 8.7 months (95% CI 7.8-10.1) OS respectively in patients’ 
group with lower grade events. 
Conclusions. Despite the small number of patients and the retrospective nature of 
the data, our analysis showed that the occurrence of neutropenia predicts response 
to treatment with ramucirumab and paclitaxel in patients with metastatic gastric 
cancer. 
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Introduction 
Ramucirumab is a human IgG 1 monoclonal antibody against vascular endothelial 
growth factor receptor 2 (VEGFR2) that prevents ligand binding and receptor-
mediated pathway activation in endothelial cells, resulting in the inhibition of 
angiogenesis [1]. Two-phase III clinical trials have shown that ramucirumab is 
effective and safe in metastatic gastric cancer [2,3]. In 2014, the REGARD trial 
showed that ramucirumab reported a survival benefit of about 2 months against 
placebo [2]. In addition, the RAINBOW trial investigated ramucirumab or placebo 
plus paclitaxel in patients with advanced gastric cancer [3], reporting an increased 
overall survival (OS) in the ramucirumab plus paclitaxel group compared to the 
placebo plus paclitaxel group (median 9.6 months versus 7.4 months respectively; 
hazard ratio (HR)=0.81). Among secondary endpoints, the progression-free survival 
(PFS) was longer in the experimental arm (2.7 versus 4.4 months; HR = 0.63) and 
the response rate (RR) was 28% for ramucirumab plus paclitaxel versus 16% for the 
control arm. Based on these results, ramucirumab monotherapy or in combination 
with paclitaxel is widely considered the standard option for patients with metastatic 
gastric cancer progressed after a first-line of chemotherapy. Additional confirmation of 
ramucirumab validity for gastric cancer comes from the RAMoss study that evaluated 
the safety and efficacy profile of ramucirumab in the “real-life setting” from 25 Italian 
hospitals recruiting more than 150 patients [4]. After a median follow-up of 11 
months, median OS was 8.3 months and median PFS was 4.5 months for patients 
treated with ramucirumab plus paclitaxel.  
Recently, an exposure-efficacy analysis of ramucirumab from the REGARD and 
RAINBOW trials suggested a positive relationship between efficacy and ramucirumab 
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exposure. In RAINBOW trial, grade ≥3 adverse events such as hypertension, 
leukopenia, and neutropenia significantly correlated with ramucirumab minimum 
trough concentration at steady state (Cmin,ss), that was a significant predictor of OS 
and PFS [5], suggesting that grade ≥3 neutropenia should be a predictor of efficacy 
in patients treated with ramucirumab plus paclitaxel. Therefore, the aim of this study 
is to evaluate whether the development of grade ≥3 neutropenia in patients with 
metastatic gastric cancer receiving ramucirumab plus paclitaxel is associated with 













Patients and Methods 
We performed a retrospective study conducted in 25 different oncological centres. 
The main methodology has already been reported [6,7] and here summarized for 
convenience. Only patients with histologically proven advanced gastric cancer 
progressed after standard first-line chemotherapy (doublet or triplet) were evaluated. 
All other eligibility criteria fit with the standard indications for ramucirumab-based 
chemotherapy. Patients with an operable disease or medical contraindication for an 
anti-angiogenetic therapy (e.g., poorly controlled hypertension, gastrointestinal 
perforation, fistulae or recent arterial thromboembolic event) were excluded. All 
patients provided written informed consent prior any medical treatment.  
The clinical, radiological and biochemical pre-treatment evaluations were performed 
within 2 weeks the treatment beginning; for adverse events, including neutropenia, 
National Cancer Institute - Common Toxicity Criteria toxicity scale V.4.2 were used 
[8]. Tumour response was assessed using RECIST 1.1 criteria [9]. 
Standard schedule of ramucirumab plus paclitaxel has been administered until 
disease progression, unacceptable toxicity or consent withdrawal. 
The aim of this study was to evaluate if the development of a grade ≥3 neutropenia 
correlates with efficacy and survival of patients treated with ramucirumab plus 
paclitaxel in a second-line regimen. For this purpose, patients were divided into two 
groups according to the development of grade ≥3 neutropenia as a cut-off. The 
primary endpoint was the PFS whereas secondary endpoints included OS and 
disease control rate (DCR). Kaplan-Meier method with log-rank test were performed 
to analyse PFS and OS in relation to the development of grade ≥3 neutropenia. 
 6 
Statistical analysis was performed using STATA software with a statistical 




The original database of patients treated from October 2015 to November 2017 was 
updated with the inclusion of patients treated up to January 2019, for a total of 53 
patients evaluated. Baseline patient characteristics are summarised in table 1. The 
vast majority of patients were males (37; 69.8%), with a median age of 66 years 
(range 38–77). Overall, 22 (41.5%) patients had an ECOG performance status of 0, 
20 (37.7%) patients received primary tumour resection surgery, 18 (33.9%) patients 
had ≥3  sites of metastasis and 20 (37.7%) patients presented peritoneal 
metastases.  
Median PFS was 4.6 months (95% CI 4-6.1) and median OS was 8.9 months (95% 
CI 8-11); no complete responses (CR) were observed and DCR was 75.5% (40/53 
patients) (table 2). 
 
Neutropenia and clinical outcome 
Ten patients (26.5%) developed grade ≥3 neutropenia during treatment (1 patient 
reported grade 4 neutropenia); however, none of the patients discontinued 
ramucirumab plus paclitaxel because of neutropenia occurrence. Among these 10 
patients with grade ≥3 neutropenia, treatment delay occurred in 4 (40%) patients, 
with an average delay of 7 days. A dose reduction of paclitaxel was required for 3 
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(30%) patients. No febrile neutropenia occurred and no granulocyte colony-
stimulating factor (G-CSF) was used to treat neutropenia.  
Patients who developed grade ≥3 neutropenia had a median PFS of 6.6 months 
(95% CI 3.3-8.4) in comparison to the PFS of 4.4 months (95% CI 3.9-5.2) for 
patients with grade <3 neutropenia (p=0.02) (Figure 1). Patients with grade ≥3 
neutropenia had a median OS of 11.9 months (95% CI 5.9-13.1) while, in contrast, 
patients with grade <3 neutropenia reported and OS of 8.7 months (95% CI 7.8-10.1) 
(p=0.04) (Figure 2). DCR was achieved by 90% of patients with grade ≥3 
neutropenia and by 72.1% of patients with no severe neutropenia (p=0.38) (Table 2). 
After adjusting for clinical covariates (peritoneal metastases, ECOG PS, number of 
metastatic sites, presence of a primary tumour, time-to-progression since prior 
therapy, tumour differentiation grade), grade ≥3 neutropenia showed an hazard ratio 
(HR) of 0.44 for PFS (HR=0.44, 95% CI 0.21-0.94, p= 0.03) and of 0.45 for OS 
(HR=0.45, 95% CI 0.20-0.99, p=0.05).  
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Discussion 
Inhibition of angiogenesis is still one of the most important approaches in treating 
patients with metastatic solid tumours [10]. The combination of paclitaxel 
chemotherapy with the ramucirumab antiangiogenetic therapy is now considered the 
gold standard in second-line treatment for patients with metastatic gastric cancer who 
progressed after standard first-line chemotherapy. Neutropenia is a possible side 
effect during therapy with paclitaxel plus ramucirumab as reported in the RAINBOW 
trial, where more than the 50% of patients developed neutropenia and more than 
40% of patients developed grade ≥3 neutropenia [3]. In the RAMoss Study, grade ≥3 
neutropenia was observed in 5.4% of patients who received paclitaxel plus 
ramucirumab. In the current study, about the 26% of patients developed grade ≥3 
neutropenia and, despite the small patients’ group size, these patients had a longer 
PFS and OS (Figure 1,2) than those with  grade <2 neutropenia [4]. A recent 
pharmacokinetic analysis of both REGARD and RAINBOW phase-III trials showed 
that grade ≥3 neutropenia significantly correlated with efficacy in the 321 patients 
treated with ramucirumab plus paclitaxel from the RAINBOW study [5]. In addition, 
another exploratory analysis of efficacy and safety of ramucirumab, conducted in 
East Asian patients from the RAINBOW trial [11], showed that efficacy of 
ramucirumab plus paclitaxel is related to the development of grade ≥3 leukopenia 
and neutropenia, but not hypertension [11]. These data suggest that higher grade 
adverse events caused by therapy are related to a higher ramucirumab exposure that 
may result in longer survival. Although our data seem to confirm the role of grade ≥3 
neutropenia as a predictor of efficacy during paclitaxel plus ramucirumab therapy, the 
small sample size of our study did not allow to perform a deeper stratification of 
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patients according to all grades of neutropenia and, consequently, the possible role 
of different grades of neutropenia remains unclear.  
To date, there is a strong need to discover possible predictors of ramucirumab 
efficacy in metastatic gastric cancer. Statistically significant prognostic factors of 
efficacy of ramucirumab plus paclitaxel in the analysis of REGARD and RAINBOW 
trials and other retrospective studies are reported in Tables 3 and 4 respectively. In 
2017, a pooled analysis from the REGARD and RAINBOW phase III trials evaluated 
more than 1000 patients in order to discover baseline prognostic factors of patients’ 
survival treated with ramucirumab [12]. A total of 41 baseline clinical and laboratory 
factors were analysed; the authors found 12 prognostic factors of poor survival 
(Table 3). In addition, data from baseline prognostic quality of life parameters 
showed that appetite loss is also an independent prognostic factor. In the RAMoss 
study, the presence of peritoneal metastases and ECOG performance status were 
independent poor prognostic factors [4] (Table 4). In 2018, two small studies showed 
that hypertension may be predictive of better outcomes in patients affected by gastric 
cancer who were treated with paclitaxel plus ramucirumab [6,13] (Table 4). However, 
data on the role of hypertension as a side effect related to efficacy of an 
antiangiogenic drug is well established in other several tumours in addition to gastric 
cancer [14-17]. Recently, a multicenter retrospective study aimed to evaluate the 
correlations between Body Weight Loss, Body Mass Index and clinical outcomes of 
metastatic gastric cancer patients treated with second-line ramucirumab-based 
therapy [18]. The study showed that Body Weight Loss seems not to have correlation 
with clinical outcome whereas Body Mass Index and ECOG performance status 
remain major prognostic factors (Table 4). However, the authors found a possible 
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explanation for the lack of prognostic effect of Body Weight Loss in the proportion of 
patients underwent surgery (more than the half) [18]. Finally, two retrospective 
analysis confirmed the efficacy of ramucirumab in patients with ascites and across 
age [19,20]. In this setting, our study provides a possible predictor of efficacy during 
the treatment with ramucirumab and not only a baseline clinical pathological factor  
as reported by the vast majority of published studies.  
 
Our study presents several limitations that we need to report: first, the retrospective 
nature of the data; secondly, the small number of patients evaluated and the absence 
of a control arm. However, although it is difficult to draw a definitive conclusion, we 
observed a strong correlation between the occurrence of grade ≥3 neutropenia and 
the response to ramucirumab therapy.  
In conclusion, ramucirumab-induced neutropenia is a predictor factor of treatment 
efficacy and survival in patients with metastatic gastric cancer treated with the 
combination of ramucirumab plus paclitaxel. Prospective large-scale trials are 
needed to further confirm these results. 
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Legends 
Figure 1: A) Estimated PFS for ramucirumab and paclitaxel in patients with grade ≥3 neutropenia (blue) or without (red). 
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